The aggressive low density lipoprotein lowering controversy

Journal of the American College of Cardiology

Volumn 36, Issue 4, 2000, Pages 1419-1425

  Forrester, James S ^a   Bairey Merz, C Noel ^a   Kaul, Sanjay ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; RISK MANAGEMENT; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0033820204     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00829-9     Document Type: Article

References (49)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levers: Results of AFCAPS/TexCAPS
6. Statin trials and goals of cholesterol-lowering therapy
7. Is relationship between serum cholesterol and risk of death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
8. Range of serum cholesterol values in the population developing coronary artery disease
9. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations
10. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
11. Relationship between LDL-C changes and CHD event reduction with pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS)
12. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
13. On the relationship between cholesterol lowering and coronary disease event rate
14. Serum cholesterol in young men and subsequent cardiovascular disease
15. Changes in serum cholesterol level and mortality: The Finnish cohorts of the seven countries study
16. Long-term effects of pravastatin on plasma concentration of C-reactive protein
17. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients
18. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
19. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: A report of the Regression Growth Evaluation Statin Study (REGRESS)
20. Lipid lowering versus revascularization: An idea whose time (for testing) has come
21. The influence of pre-treatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials
22. Lipid-lowering interventions in angiographic trials
23. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease
24. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: New evidence, implications and outstanding issues
25. Effects of lipid lowering therapy on progression of coronary and carotid artery disease
26. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: 25-Year follow-up of the seven countries study
27. Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries
28. Pravastatin therapy in primary moderate hypercholesterolaemia: Changes in metabolism of apolipoprotein B-containing lipoproteins
29. Direct vascular effects of HMG-CoA reductase inhibitors
30. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
31. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
32. Effects of lipids and lipoproteins on thrombosis and rheology
33. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors
34. Effect of pravastatin on outcomes after cardiac transplantation
35. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
36. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
37. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
38. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
39. Is aggressive cholesterol control justified? Review of the Post-Coronary Artery Bypass Graft trial
40. Cholesterol reduction and clinical benefit: Are there limits to our expectations?
41. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans
42. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease
43. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis
44. Is there a benefit to lowering low-density lipoprotein below 100 mg/dl in patients with coronary artery disease?
45. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients
46. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
47. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
48. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
49. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program